>>> Seagate Tech beats by $0.12, reports revs in-line; guides Q4 EPS midpoint ab

Seagate Tech beats by $0.12, reports revs in-line; guides Q4 EPS midpoint above consensus, revs midpoint below consensus (44.94)
  • Reports Q3 (Mar) earnings of $0.83 per share, excluding non-recurring items, $0.12 better than the S&P Capital IQ Consensus of $0.71; revenues of $2.31 bln vs the $2.32 bln S&P Capital IQ Consensus.
  • Co sees Q4 EPS of ~$0.83 (+/- 5%), excluding non-recurring items, vs. $0.81 S&P Capital IQ Consensus; sees Q4 revs of ~$2.32 bln (plus or minus 5%) vs. $2.34 bln S&P Capital IQ Consensus.
  • "We began shipping the industry's first 16-terabyte high capacity drives in the fiscal third quarter and expect to ramp high volume production in the second half calendar 2019.

>>> General Motors misses by $0.02, misses on revs; reaffirms FY19 guidance (40

General Motors misses by $0.02, misses on revs; reaffirms FY19 guidance (40.01)
  • Reports Q1 (Mar) earnings of $1.10/share, excluding a $0.31/share benefit from Lyft and PSA revaluations, vs. the S&P Capital IQ Consensus of $1.12; revenues fell 3.4% year/year to $34.88 bln vs the $35.56 bln S&P Capital IQ Consensus.
  • North American segment adj. EBIT $1.9 bln from 2.2 bln last year; International breakeven.
  • Results were affected by planned SUV downtime partially offset by strong pickup truck performance.
  • Full-size truck launch ahead of plan; average transaction prices for all-new crew cabs up $5,800 vs. outgoing models.
  • Co reaffirms guidance for FY19, sees EPS of $6.50-7.00, excluding non-recurring items, vs. $6.50 S&P Capital IQ Consensus; adjusted automotive free cash flow of $4.5-6.0B. Execution of company's transformation cost savings of $2 to $2.5 billion through 2019 remains on track.
  • "GM's first-quarter operating results were in line with expectations we shared in January. My confidence in the year ahead remains strong, driven by our all-new full-size truck launch and our ongoing business transformation.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:

  • TTS -18.4%, CGNX -15.6%, CRTO -15.1%, TREX -12.5%, IIN -10.9% (appoints CFO Scott Longval to additional role of COO; elects Philip Smith as Chairman of the Board), HLIT -10.5%, GHL -8.3%, GOOG -7.6%, DBD -7.5%, CNX -6.8%, TXRH -6.7%, AOS -5.4%, WDC -4.9%, NBIX -4.9%, CHE -4.7%, CHGG -4.3%, LOGI -4.2%, MGM -3.8%, SXI -3.4% (also announces acquisition of Genius Solutions Engineering Company), PSX -3.4%, LLY -3.3%, ORAN -2.8%, PCH -2.7%, ETH -2.3%, GLW -2.3%, I -2%, BHGE -1.9%, LEG -1.5%, LL -1.4%, CRSP -1.4%, HSII -1.1%

Other news:

  • MBIO -9.6% (announces proposed public offering of common stock; size not disclosed)
  • PRGO -7.2% (received revised Notice of Proposed Adjustment from the IRS team auditing Athena Neurosciences)
  • MGTA -7.1% (files for 4.25 mln share common stock offering )
  • HQY -4% (under pressure after Reuters reported the company made WageWorks bid)
  • RGEN -2.7% (announces public offering of $175 mln in shares of its common stock)
  • ADC -2% (prices 2.75 mln shares of common stock at $65.85 per share in connection with the forward sale agreements)
  • THO -1.4% (files for 2,256,492 share common stock offering by selling shareholders)

Analyst comments:

  • N/A.

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • PI +22.9%, GE +11%, SANM +10.4%, CURO +10.3%, GDI +7.5%, WWD +7.4%, MEDP +6.4%, NXPI +6.2%, YUMC +5.6%, AMRC +5%, BRX +4.8%, APRN +4.8%, AKS +4.5%, VRNS +4.2%, THC +3.4%, MLM +3.3%, CLR +3.1%, CMI +3%, MOH +2.7%, AUDC +2.5%, FDC +2.4%, SBAC +2.3%, MUSA +2.2%, BP +2.2%, TNET +2%, ECA +2%, RIG +1.9%, LDOS +1.7%, CCEP +1.6%, COP +1.4%, APTS +1.3%, MRK +1.3%, CHTR +1.1%, ARCC +1%, PFE +1%

Other news:

  • SYBX +31.1% (presents data demonstrating its development of a robust and reproducible process to generate a solid oral formulation of its Synthetic Biotic medicine, SYNB1618)
  • GTHX +16.4% (provided a regulatory update on trilaciclib)
  • WAGE +13.9% (confirms that it has received an unsolicited, non-binding proposal from HealthEquity (HQY))
  • APTX +7.9% (reports 'positive' results from Phase 1 study of NYX-458 in clinical development for the treatment of cognitive impairment associated with Parkinson's disease) NPTN +5.4% (initiated with Buy at MKM Partners)
  • ARNC +1.4% (ahead of earnings tomorrow before the open)
  • BDX +1.4% (receives FDA approval for BD ChloraPrep skin preparation with sterile solution)
  • PNNT +1.3% (ticking higher; initiated with Outperform at Raymond James)

Analyst comments:

  • OI +1.3% (upgraded to Buy from Hold at SunTrust)
  • ON +1.3% (upgraded to Buy from Hold at Jefferies)

>>> Sabre beats by $0.03, beats on revs; lowers FY19 revs, FCF guidance (22.86)

Sabre beats by $0.03, beats on revs; lowers FY19 revs, FCF guidance (22.86)
  • Reports Q1 (Mar) earnings of $0.34 per share, excluding non-recurring items, $0.03 better than the S&P Capital IQ Consensus of $0.31; revenues rose 6.2% year/year to $1.05 bln vs the $1.04 bln S&P Capital IQ Consensus.
  • Co lowers guidance for FY19, sees FY19 revs of $3.965-4.045 bln (Prior $4.005-4.085 bln) vs. $4.06 bln S&P Capital IQ Consensus; sees FCF of ~$455 mln (Prior ~$485 mln)
    • "Our solid first quarter results provide a strong foundation to build on over the balance of the year. As we look at the rest of 2019, we believe our business is solid," said Doug Barnett, CFO. "As you have seen and read about, an Airline Solutions customer in India has recently suspended flight operations. Additionally, our deepest sympathies are with the families and loved ones impacted by the recent accidents involving the 737 MAX aircraft at two of our Airline Solutions customers that resulted in the grounding of that aircraft. There is an obvious near-term impact to our business related to these events that is reflected in our updated guidance. Although we have observed a modest slowdown in global GDS industry bookings, our expectations for continued share gain and our regional and customer mix give us confidence in the underlying performance of the business...We have revised our full year 2019 expectations to reflect both the airline customer's suspended operations and the impact of the 737 MAX aircraft situation."
  • Separately, the co and Visa (V) announced a partnership to support the growth of business-to-business (B2B) virtual payments in the travel industry. Under this agreement, travel buyers and suppliers will be able to pay and get paid with virtual Visa commercial cards, through the Sabre Virtual Payments solution

Reuters : Boxed in: $1 billion of Iranian crude sits at China's Dalian port


Boxed in: $1 billion of Iranian crude sits at China's Dalian port

SINGAPORE (Reuters) - Some 20 million barrels of Iranian oil sitting on China’s shores in the northeast port of Dalian for the past six months now appears stranded as the United States hardens its stance on importing crude from Tehran.

Iran sent the oil to China, its biggest customer, ahead of the reintroduction of U.S. sanctions last November, as it looked for alternative storage for a backlog of crude at home.

The oil is being held in so-called bonded storage tanks at the port, which means it has yet to clear Chinese customs. Despite a six-month waiver to the start of May that allowed China to continue some Iranian imports, shipping data shows little of this oil has been moved.

Traders and refinery sources pointed to uncertainty over the terms of the waiver and said independent refiners had been unable to secure payment or insurance channels, while state refiners struggled to find vessels.

The future of the crude, worth well over $1 billion at current prices, has become even more unclear after Washington last week increased its pressure on Iran, saying it would end all sanction exemptions at the start of May.

“No responsible Chinese company with any international exposure will have anything to do with Iran oil unless they are specifically told by the Chinese government to do so,” said Tilak Doshi of oil and gas consultancy Muse, Stancil & Co in Singapore.

Iran previously stored oil in 2014 at Dalian during the last round of sanctions that was later sold to buyers in South Korea and India.

China last week formally complained to the United States over the unilateral Iran sanctions, but U.S. officials have said Washington is not considering a further short-term waiver or a wind-down period.

The 20 million barrels is equal to about a month’s worth of China’s imports from Iran over the past six months, or about two days of the country’s total imports.

Iran says it will continue to export oil in defiance of U.S. sanctions.

A senior official with the National Iranian Tanker Company (NITC), who spoke on condition of anonymity, told Reuters: “We will continue to sell our oil.”

“Iran is now desperate and will deal with anyone with steep discounts as long as they get paid somehow,” said Doshi.

SOME OIL TAKEN
Some Iranian oil sent to Dalian has moved, according to a ship tracking analyst at Refinitiv.

Dan, a supertanker owned by NITC moved 2 million barrels of oil from Dalian more than 1,000 km (620 miles) to the south to the Ningbo Shi Hua crude oil terminal in March, according to Refinitiv data.

Ningbo is home to Sinopec’s Zhenhai refinery, one of the country’s largest oil plants with a capacity of 500,000 barrels a day and a top processor of Iranian oil.

Sinopec declined to comment.


The Iranian tanker was chartered by state-run Chinese trader Zhuhai Zhenrong Corp, according to Refinitiv analyst Emma Li. The NITC official confirmed the oil was taken by Zhuhai Zhenrong.

Zhenrong was started in the 1990s and brokered the first oil supply deals between Iran and China. At that time, Iran was supplying oil to China to pay for arms supplied by Beijing during the 1980-88 Iran-Iraq war. Zhuhai Zhenrong still specializes mainly in buying Iranian oil.

An official at the general manager’s office with Zhuhai Zhenrong’s office in Beijing said he could not immediately comment. The company did not reply to a fax seeking comment.

For now, more Iranian oil is heading to China, with the supertankers Stream and Dream II due to arrive in eastern China from Iran on May 5 and May 7, respectively, Refinitiv data showed.

Some of this crude may be from Chinese investments into Iranian oilfields, a sanctions grey area.

Whether China will keep buying oil from Iran remains unclear, but analysts at Fitch Solutions said in a note “there may be scope for imports via barter or non-compliance from ... China.”

Muse, Stancil & Co’s Doshi said the only way to get the Iranian oil out of Dalian now was by cheating.

“Only rogue parties might try to cheat the system and try to pass the Iranian oil at Dalian as something else via fraudulent docs. But I doubt this is easy or can amount to much in terms of volume.”

>>> Hubbell beats by $0.02, misses on revs; reaffirms FY19 EPS guidance (123.26

Hubbell beats by $0.02, misses on revs; reaffirms FY19 EPS guidance (123.26)
  • Reports Q1 (Mar) earnings of $1.57 per share, excluding non-recurring items, $0.02 better than the S&P Capital IQ Consensus of $1.55; revenues rose 9.7% year/year to $1.09 bln vs the $1.1 bln S&P Capital IQ Consensus; +5% organic.
  • Co reaffirms guidance for FY19, sees EPS of $7.80-8.20, excluding non-recurring items, vs. $8.07 S&P Capital IQ Consensus. For the full year 2019, Hubbell continues to anticipate end markets will grow approximately 2% to 3% in the aggregate and approximately 1% growth from acquisitions. This end market outlook includes growth of 1 - 3% in non-residential markets, 0 - 2% in residential markets, 2 - 4% in oil and gas markets, 2 - 4% in electrical T&D markets, and 2 - 4% in industrial markets.
  • "Hubbell achieved another strong quarter of organic growth," said David G. Nord, Chairman, President and Chief Executive Officer. "We remain disciplined on driving price to offset inflationary headwinds, while end markets overall continued to grow at a modest pace as expected. Most major end markets expanded in the quarter, and we saw particular strength in industrial, gas distribution, and electrical T&D. Oil markets were soft in the quarter, while Aclara revenue contribution was ahead of expectations driven by strong customer demand.

>>> Criteo beats by $0.17, reports revs ex-TAC in-line; guides Q2 revs ex-TAC be

Criteo beats by $0.17, reports revs ex-TAC in-line; guides Q2 revs ex-TAC below consensus, lowers full year rev ex-TAC outlook but maintains adjusted EBITDA margin (22.45)
  • Reports Q1 (Mar) earnings of $0.60 per share, excluding non-recurring items, $0.17 better than the S&P Capital IQ Consensus of $0.43; revenues ex-TAC fell 2.0% year/year to $235.7 mln vs the $234.2 mln S&P Capital IQ Consensus and vs prior guidance of $233-235 mln.
  • Co issues downside guidance for Q2, sees Q2 revs ex-TAC of $221-224 mln vs. $235.0 mln S&P Capital IQ Consensus.
  • Co lowers full year guidance for revenue ex-TAC growth to +0-2% at constant currency vs prior guidance of +3-6% at constant currency. Despite the lower guidance for Revenue ex-TAC, co maintains its expectation for an adjusted EBITDA margin of approximately 30% of Revenue ex-TAC for fiscal year 2019